Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Acorda Therapeutics announces positive AMPYRA® (dalfampridine) Phase 2 data in people with post-stroke deficits
Progressive outer retinal necrosis in a multiple sclerosis patient on natalizumab.
Bullous pemphigoid in a patient with multiple sclerosis being treated with human immunoglobulin.
[Budget impact analysis of the first-line treatment of relapsing remitting multiple sclerosis in Spain. Reply].
Physical Activity Behavior Change in Persons With Neurologic Disorders: Overview and Examples From Parkinson Disease and Multiple Sclerosis.
The little compound that could: how phenytoin changed drug discovery and development.
Dynamic walking features and improved walking performance in multiple sclerosis patients treated with fampridine (4-aminopyridine).
Ophthalmic Evaluations in Clinical Studies of Fingolimod (FTY720) in Multiple Sclerosis.
Exogenous schwann cells migrate, remyelinate and promote clinical recovery in experimental auto-immune encephalomyelitis.
Multiple sclerosis and progressive resistance training: a systematic review.
[Diagnosis of multiple sclerosis - the 2010 revision of the McDonald criteria.]
Periventricular lesions help differentiate neuromyelitis optica spectrum disorders from multiple sclerosis.
Genzyme’s Lemtrada™ approved in Canada for treatment of multiple sclerosis
The risk of multiple sclerosis in bereaved parents: A nationwide cohort study in Denmark.
High dose naltrexone for dyskinesias induced by levodopa.
Safety Study of RTL1000 (Recombinant T Cell Receptor Ligand) in Subjects with Multiple Sclerosis
Discovery of fingolimod, the sphingosine 1-phosphate receptor modulator and its application for the therapy of multiple sclerosis.
Vision in a Phase 3 Trial of Natalizumab for Multiple Sclerosis: Relation to Disability and Quality of Life.
Phase IV Study Reports Multiple Sclerosis Success with Teriflunomide
Medicare Part D payments for neurologist-prescribed drugs.
Ustekinumab induction and maintenance therapy in refractory Crohn's disease.
High dose thiamine improves fatigue in multiple sclerosis.
Alemtuzumab as rescue therapy in a cohort of 16 aggressive multiple sclerosis patients previously treated by Mitoxantrone: an observational study.
Subclinical CNS Inflammation as Response to a Myelin Antigen in Humanized Mice.
Intense immunosuppression in chronic progressive multiple sclerosis: the Kaiser study.

Pages